8-K: Adial Pharmaceuticals Terminates Consulting Agreement with Chief Medical Officer
Management Change Announcement
Adial Pharmaceuticals has terminated its consulting agreement with Dr. Bankole A. Johnson, resulting in his departure as Chief Medical Officer effective May 17, 2024.
Summary
- Adial Pharmaceuticals has terminated its consulting agreement with Dr. Bankole A. Johnson.
- The consulting agreement was originally entered into on March 24, 2019, and amended on March 22, 2022, and September 8, 2022.
- The termination of the agreement is effective May 17, 2024.
- As a result of the termination, Dr. Johnson will no longer serve as the company's Chief Medical Officer, also effective May 17, 2024.
Sentiment
Score: 5
Explanation: The document reports a change in management, which is a neutral event. The impact on the company is not clear from the document.
Negatives
- The termination of the consulting agreement results in the departure of the Chief Medical Officer.
Risks
- The departure of the Chief Medical Officer could potentially impact the company's medical and clinical strategies.
Industry Context
Changes in executive leadership are not uncommon in the pharmaceutical industry, often reflecting strategic shifts or operational adjustments.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Medical Officer | Dr. Bankole A. Johnson | 2024-05-17 | Termination of consulting agreement |
Stakeholder Impact
- Shareholders may react to the change in executive leadership.
- Employees may experience uncertainty due to the change in management.
Key Dates
| Date | Description |
|---|---|
| 2019-03-24 | Original consulting agreement with Dr. Bankole A. Johnson was entered into. |
| 2022-03-22 | Consulting agreement with Dr. Bankole A. Johnson was amended. |
| 2022-09-08 | Consulting agreement with Dr. Bankole A. Johnson was amended. |
| 2024-04-10 | Adial Pharmaceuticals provided notice of termination of the consulting agreement. |
| 2024-05-17 | Termination of consulting agreement and Dr. Johnson's departure as Chief Medical Officer are effective. |
Keywords
Chief Medical Officer, consulting agreement, termination, Adial Pharmaceuticals, management change
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.